Jereme Sylvain and Dexcom are combining finance and operations leadership as the glucose-biosensing company prepares for its next phase of scale. Dexcom promoted Sylvain to chief operating officer in addition to his role as chief financial officer, giving him oversight of the company’s global operations and quality teams.
Sylvain joined Dexcom in 2018 and has been executive vice president and CFO since 2021. The expanded remit is designed to create greater alignment, speed and accountability across the company, according to Dexcom’s announcement. CEO Jake Leach called Sylvain an exceptional leader and said his business understanding, operational discipline and customer focus made him the right leader for the broader role.
This is a role-design decision as much as a promotion. Combining the CFO and COO briefs can shorten the distance between resource allocation and operating execution. It can also make trade-offs more explicit: investment in capacity, quality systems, commercial growth and margin expansion will sit closer to one decision-maker. The model works only if the organization keeps strong challenge mechanisms around finance, quality and customer commitments.
Dexcom’s timing is consequential. The company says its technology has changed how people manage diabetes and track glucose, and it is pursuing a vision to empower millions more people to take control of their health. That ambition makes operational reliability a leadership issue, not simply a back-office concern. Quality, supply, manufacturing and service decisions will shape whether growth can scale without weakening trust.
The company credits Sylvain with building a strong finance leadership team and guiding growth and margin expansion. The COO appointment now tests whether that financial perspective can be translated into faster cross-functional decisions. It also gives the board a single executive accountable for the link between the plan and the machinery required to deliver it.
The indicators to watch are straightforward: execution speed, quality performance, supply resilience and the company’s ability to scale while preserving margin discipline. Dexcom has not announced a separate effective date on the investor-relations release; the substance is clear now. Sylvain’s expanded mandate places operational excellence alongside finance at the center of the company’s growth story.
For a company scaling a mission-critical product, that connection between capital and delivery can be a competitive capability.
